Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(20%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
20%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution1 total trials
Phase 1Safety & dosage
1(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

66.7%

2 of 3 finished

Non-Completion Rate

33.3%

1 ended early

Currently Active

1

trials recruiting

Total Trials

5

all time

Status Distribution
Active(2)
Completed(2)
Terminated(1)

Detailed Status

Completed2
Withdrawn1
Not yet recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
1
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (100.0%)

Trials by Status

completed240%
withdrawn120%
not_yet_recruiting120%
active_not_recruiting120%

Recent Activity

1 active trials
Showing 5 of 5
not_yet_recruiting

Long-term Follow-up of Pituitary and Hypothalamic Dysfunction in Children Who Have Suffered Moderate to Severe Head Trauma Included in the ENDOC TC Cohort

NCT07533435
active_not_recruiting

Mixed Methods Study to Assess Family Members Unmet Needs in an Oncology Setting

NCT06142071
withdrawnphase_1

Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)

NCT01048983
completed

Quality of Life After Esophagectomy for Cancer

NCT00798746
completed

Long-Term Follow Up Study for AMD3100 Patients

NCT00476294

Clinical Trials (5)

Showing 5 of 5 trials
NCT07533435

Long-term Follow-up of Pituitary and Hypothalamic Dysfunction in Children Who Have Suffered Moderate to Severe Head Trauma Included in the ENDOC TC Cohort

Not Yet Recruiting
NCT06142071

Mixed Methods Study to Assess Family Members Unmet Needs in an Oncology Setting

Active Not Recruiting
NCT01048983Phase 1

Reducing Symptom Burden - Non Small Cell Lung Cancer (NSCLC)

Withdrawn
NCT00798746

Quality of Life After Esophagectomy for Cancer

Completed
NCT00476294

Long-Term Follow Up Study for AMD3100 Patients

Completed

All 5 trials loaded

Drug Details

Intervention Type
OTHER
Total Trials
5